The mental toll of wildfire smoke
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
7 minutes ago
- National Post
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
Article content Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa ® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research Article content BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa ® technology. Article content These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa ® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers. Article content Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa ® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. Article content 'The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's,' said Masoud Toloue, PhD, CEO of Quanterix. 'Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we're advancing the future of precision diagnostics across neurology, oncology, and immunology.' Article content The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia. Article content To learn more about the new assays or Quanterix's expanded capabilities, visit or stop by the Quanterix booth at AAIC 2025. Article content About Quanterix Article content Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at Article content Article content Article content Article content Contacts Article content Media Contact: Marissa Klaassen (781) 913.8036 media@ Article content
National Post
7 minutes ago
- National Post
Zetagen Therapeutics Secures Composition-of-Matter Patents from USPTO for Novel Breast Cancer Platform
Article content (Composition-of-matter and compound patents are valuable forms of intellectual property within the pharmaceutical industry) Article content Article content Expanded Protection & Strategic Value – These patents underscore the company's defensible innovation, strengthening its appeal to investors, partners, and future acquirers Article content SYRACUSE, N.Y. — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via intratumorally administration, for primary and metastatic breast cancers, announced today they have successfully secured the foundational Composition-of-Matter patents and claims from the USPTO for their proprietary breast cancer platform. Article content 'Securing these allowances and composition-of-matter patents for our intratumorally administered breast cancer therapeutics represents a strategic leap forward in our mission to redefine oncologic care,' Article content said Joe C. Loy, CEO of Zetagen Therapeutics Article content . 'This latest patent protects the molecular uniqueness of our drug ZetaPrime™ and affirms the disruptive potential in our pursuit to minimize off target side effects of conventional chemotherapeutics. We are proud to advance precision therapies designed to target tumors directly and deliver meaningful hope to patients with limited options.' Article content Zetagen Therapeutics has built a robust intellectual property portfolio anchored in its groundbreaking discoveries in intratumorally drug administration for both primary and metastatic breast cancer. The company's IP estate—which now includes multiple composition-of-matter patents— focuses on proprietary and established molecules designed to be delivered directly into tumors, reducing systemic toxicity and off-target side effects. This precision method not only protects healthy tissue but also holds the potential to significantly improve survival outcomes by enhancing therapeutic efficacy at the site of disease. Zetagen' s growing suite of patents underscores its commitment to redefining standards of care and advancing targeted oncology innovation. Article content said Bryan S. Margulies, Ph.D., CSO of Zetagen Therapeutics. Article content 'By securing these patents, we validate the unique molecular design of our compounds and strengthen our pursuit of transformative therapies for underserved patient populations.' Article content Zetagen has enlisted Foley & Lardner LLP as its intellectual property counsel and maintains a collaborative professional relationship with Steve Maebius, Esq. Foley & Lardner LLP is a prominent law firm with global reach and specialized expertise in Life Sciences intellectual property and strategic counsel. Article content About ZetaMet™ (Zeta-BC-003) – Lead Drug Candidate: Article content ZetaMet™ is a groundbreaking molecular pathway drug, targets metastatic breast cancer in bone, ceasing lytic activity, inhibits pain, and regenerates new bone all via locoregional administration, 30-minute outpatient procedure, without systemic limitation, minimizing skeletal related events (SRE) while increasing survival rates. Article content ZetaMet™ has been awarded 2x FDA Breakthrough Designations and has been approved in the treatment of 8x Compassionate Use stage 4 cancer patients in the US and Canada. Article content ZetaMet™ has demonstrated cross-species efficacy at consistent concentrations, with findings published in several peer-reviewed journals—underscoring its translational promise from lab to clinic. Notably, these individuals had previously failed to respond to standard treatments such as chemotherapy, surgery, and radiation. Article content Zetagen has successfully completed enrollment of phase 2a clinical trial for the treatment of metastatic breast cancer to the spine, University of British Columbia, preliminary results available upon request and full study results anticipated November 2025. Article content ZetaMast™ is a proprietary drug-eluting hydrogel carrier designed for locoregional administration, controlled release of small molecules in treatment of multifocal, unresectable, liver metastases from breast cancer with potential to increase survival rates. Article content Zetagen has completed preclinical studies, drug elution refinement, toxicity testing and a dose optimization study, results published in peer-review journal PLOS-One. Zetagen plans to file an IND with the FDA this fall and upon approval conduct a Phase 1b dose escalation study early 2026. Article content About ZetaPrime™ (Zeta-PBC-007) Article content ZetaPrime™ is a neo-adjuvant treatment for primary HR+ breast cancer, engineered for a locoregional administration following diagnosis. Utilizing a proprietary hydrogel-like lipid carrier, formulation enables controlled release of two small molecules— one being our novel molecular entity, and the ability to deliver other companies CDK4 or CDK4/6 protein inhibitor and any anticancer therapeutic. Designed for solubility within adipose tissue, approach targets primary breast cancer, aiming to mitigate off-target effects, reduce necessity for lumpectomies and mastectomies, postpone radiation exposure, and enhance patient survival. Article content About Zetagen Therapeutics Article content Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company, dedicated to developing proprietary carriers delivering tumoricidal therapies intratumorally via a singular injection for primary and metastatic breast cancer, minimizing patient side effects and postponing palliative radiation with the potential to increase survival rates. Article content The company's 'Zeta' platform encompasses the following breast cancer drug candidates ZetaMet™ (Zeta-BC-003), ZetaMast™ (Zeta-MBC-005) and (NEW) ZetaPrime™ (Zeta-PBC-007). To learn more, visit Article content Zetagen will attend the San Antonio Breast Cancer Symposium (SABCS) in December. Article content Forward-Looking Statements Article content This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Article content Article content Article content Article content Article content Article content
National Post
7 minutes ago
- National Post
Tractive Acquires Whistle from Mars Petcare to Accelerate Leadership in Global Pet Tech Market
Strategic Acquisition Expands U.S. Market Presence and Brings Advanced Wellness Technology to Global Pet Parent Community Article content PASCHING, Austria & SEATTLE — Tractive, the global leader in GPS tracking and pet health insights, today announced it has acquired Whistle, the connected pet wearable brand owned by Mars Petcare. This strategic acquisition adds Whistle's customer base and technology assets to Tractive, reinforcing its leadership in the fast-growing pet tech market. Founded in Austria in 2012, Tractive has established itself as the world's leading provider of smart GPS and health trackers for pets, serving over 1.4 million active users worldwide with millions of devices sold globally. Article content Now, by joining forces, we're combining the strengths of two market leaders to reinforce Tractive's global leadership and accelerate our mission to improve pet safety and health worldwide. Article content Whistle customers will have the option to transition to Tractive's highly rated platform, named #1 by Consumer Reports and recognized as the top pet tracker on Amazon and top pick by The New York Times Wirecutter. The move gives Whistle users access to Tractive's latest innovations, including resting heart rate and respiratory rate monitoring, a first in the pet GPS and health tracking category. Article content 'This acquisition is a defining moment for Tractive,' said Michael Hurnaus, CEO and co-founder of Tractive. 'It strengthens our U.S. footprint, scales our customer base, and allows us to bring cutting-edge wellness technology to even more pet parents around the world. In the United States, Whistle is recognized as the original pioneer in pet tracking and activity monitoring. Since 2013, Tractive and Whistle have been innovating in parallel, Tractive in Europe and Whistle in the U.S., shaping the future of pet tracking and wellness. Now, by joining forces, we're combining the strengths of two market leaders to reinforce Tractive's global leadership and accelerate our mission to improve pet safety and health worldwide.' Article content Tractive's smart trackers enable pet owners to locate their animals in real time and monitor comprehensive health metrics including activity, sleep, barking behavior, resting heart rate, and respiratory rate, with millions of health data points analyzed daily to generate valuable insights that ensure safety, well-being, and peace of mind for pet owners across North America and Europe. Article content With the pet industry, and especially connected pet care, growing much faster than overall consumer spending, Tractive is uniquely positioned to lead the future of pet wellness and tracking globally. Its devices offer long battery life, live GPS, health alerts, and now vital sign monitoring—delivered through a seamless subscription model across more than 175 countries. Article content Tractive is the global leader in health monitoring and GPS tracking for dogs and cats, on a mission to help pet parents keep their pets safe, healthy, and happy. Trusted by 1.4 million active users worldwide, Tractive is transforming pet care through data-driven health insights and innovative technology. Headquartered in Austria with offices in the U.S. and Germany, Tractive works with all major cellular providers across North America and Europe to ensure best-in-class coverage wherever pets roam. Article content Article content Article content Article content Contacts Article content Media Contacts: Article content Andrew Bleiman, EVP Tractive North America Article content Article content
